Fierce Survey Report Infographic

Slope’s inaugural State of Clinical Inventory and Sample Management survey gathered insights from 146 biopharma professionals on the impacts of inefficient, manual processes for managing clinical supply — lab kits, devices, ancillary supplies, and investigational product (IP) — and samples on budgets, timelines, data integrity, and patients. The survey findings highlight the pain felt by study teams as the complexity of the supply chain is not supported by standardized processes and technology. There is an acknowledgment of the problem, and yet most have not transformed the way they are operationalizing their clinical trials to address it. The existing processes currently in place are incapable of ensuring the availability of crucial clinical inventory, including lab kits, drugs, devices, and other essential supplies. Moreover, there is a significant lack of transparency regarding the biospecimen chain of custody. This lack of visibility leads to various negative consequences, such as delays in studies, reduced trial outcomes, exceeded budget limits, and most importantly, a direct impact to the performance of research sites and the well-being of their patients.